Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn expects pipeline prioritization and organizational changes to fund its priority programs into the second half of 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 into clinical development expansion following review of Phase 1 dose-escalation data.
The collaboration also will not advance the Selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities. Foghorn said FHD-909 showed a favorable safety profile at exposures exceeding preclinical targets, but efficacy was insufficient to advance. Resources will shift to wholly owned programs: a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader and an induced proximity platform. Foghorn is reducing its workforce by approximately 40%; it expects pipeline prioritization and organizational changes to extend its cash runway into the second half of 2029.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Pipeline prioritization and organizational changes are expected to extend cash runway into the second half of 2029.
- Minor point. Forward-looking: it has not happened yet and may not happen.Foghorn plans to focus resources on wholly owned programs and advance them toward the clinic.
- Minor pointFHD-909 showed a favorable safety profile at exposures exceeding preclinical targets, Foghorn said.
Negative
- Major pointFHD-909 will not advance into clinical development expansion; Foghorn said efficacy was insufficient.
- Major pointWorkforce reduction of approximately 40% accompanies the pipeline reprioritization.
- Moderate pointSelective SMARCA2 degrader development will not advance under the collaboration.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Foghorn and Lilly do not anticipate further collaboration activities.
Key Figures
- Workforce reduction
- approximately 40%
- Reduction announced alongside operating-structure changes
- Cash runway
- into the second half of 2029
- Expected runway following pipeline prioritization and organizational changes
Historical Context
-
FHD-909 continued Phase 1 dose escalation, with combination studies conditional on successful escalation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dose escalation medical
synthetic lethality medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program
- Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform
- Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately
40% workforce reduction
WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase. The Collaboration also will not be advancing the Selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities. As a result, Foghorn is prioritizing resources toward its proprietary portfolio programs with the greatest potential to address significant patient needs and create long-term value.
“While we are disappointed with the clinical results, we and Lilly developed a drug in FHD-909 that selectively hits the SMARCA2 target with a favorable safety profile at exposures that exceeded our preclinical targets. Unfortunately, the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. “We built Foghorn based on a demonstrated capability in designing drugs for challenging molecular targets, and we have leveraged this capability to build a proprietary pipeline. Today, we are committed to focusing our financial and developmental resources to advance these programs toward the clinic.”
“Foghorn is reducing its workforce by approximately
Mr. Gottschalk continued, “I would like to thank our partner Lilly for their support, as well as the patients, caregivers, investigators, study site staff, and all others who participated in and contributed to the FHD-909 clinical trial.”
About FHD-909
FHD-909 (LY4050784) is a potent, first-in-class, allosteric, and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing product candidates in oncology and in immunology & inflammation. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s preclinical programs, including its selective CBP and selective EP300 degrader programs, selective ARID1B degrader program, its induced proximity efforts, its novel oral small molecule in immunology and inflammation, and other preclinical product candidates, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why are Foghorn and Lilly not advancing FHD-909?
Foghorn said FHD-909 did not achieve the level of efficacy required to advance following review of Phase 1 dose-escalation data. The companies will not move the program into clinical development expansion, despite a favorable safety profile at exposures exceeding preclinical targets.
How far does Foghorn expect its cash runway to extend after restructuring?
Foghorn expects pipeline prioritization and organizational changes to extend cash funding for its priority programs into the second half of 2029. The changes include an approximately 40% workforce reduction and a focus on its proprietary pipeline.